Literature DB >> 20422470

Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children.

Masayuki Nagasawa, Noriko Mitsuiki, Toshiaki Ono, Masatoshi Takagi, Hiromi Oda, Masato Yasuhara, Shuki Mizutani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20422470     DOI： 10.1007/s12185-010-0572-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Masayuki Towatari; Masamitsu Yanada; Noriko Usui; Jin Takeuchi; Isamu Sugiura; Makoto Takeuchi; Fumiharu Yagasaki; Yasukazu Kawai; Shuichi Miyawaki; Shigeki Ohtake; Itsuro Jinnai; Keitaro Matsuo; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

2.  Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.

Authors:  T Nishikawa; Y Okamoto; T Tanabe; Y Shinkoda; Y Kodama; M Higashi; H Hirano; K Arita; Y Kawano
Journal:  Bone Marrow Transplant       Date:  2009-08-17       Impact factor: 5.483

3.  Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Authors:  N Bleyzac; G Souillet; P Magron; A Janoly; P Martin; Y Bertrand; C Galambrun; Q Dai; P Maire; R W Jelliffe; G Aulagner
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

4.  Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.

Authors:  A M Bolinger; A B Zangwill; J T Slattery; L J Risler; D H Sultan; D V Glidden; D Norstad; M J Cowan
Journal:  Bone Marrow Transplant       Date:  2001-12       Impact factor: 5.483

5.  Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.

Authors:  Tal Schechter; Yaron Finkelstein; John Doyle; Zulfikarali Verjee; Myla Moretti; Gideon Koren; L Lee Dupuis
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

6.  Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.

Authors:  G Vassal; G Michel; H Espérou; J C Gentet; D Valteau-Couanet; F Doz; F Mechinaud; C Galambrun; B Neven; H Zouabi; L Nguyen; C Puozzo
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-29       Impact factor: 3.333

7.  Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.

Authors:  L'Aurelle Johnson; Paul J Orchard; K Scott Baker; Richard Brundage; Qing Cao; Xinjing Wang; Erica Langer; Sharein Farag-El Maasah; Julie A Ross; Rory Remmel; Pamala A Jacobson
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126
  7 in total
  2 in total

1.  Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Authors:  Erika Watanabe; Takuro Nishikawa; Kazuro Ikawa; Hiroki Yamaguchi; Takanari Abematsu; Shunsuke Nakagawa; Koichiro Kurauchi; Yuichi Kodama; Takayuki Tanabe; Yuichi Shinkoda; Kazuaki Matsumoto; Yasuhiro Okamoto; Yasuo Takeda; Yoshifumi Kawano
Journal:  Int J Hematol       Date:  2015-08-05       Impact factor: 2.490

2.  Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.

Authors:  S Maheshwari; A Kassim; R F Yeh; J Domm; C Calder; M Evans; B Manes; K Bruce; V Brown; R Ho; H Frangoul; E Yang
Journal:  Bone Marrow Transplant       Date:  2013-12-09       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.